Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Perioperative Panitumumab with EOX in Gastroesophageal Adenocarcinoma
NCT00667420Phase 2Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2008
- Primary completion
- Jun 2011
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in esophageal adenocarcinoma (EAC) and gastric adenocarcinoma, sponsored by Massachusetts General Hospital. Primary endpoint: Safety and Tolerability. Started Apr 2008; status: terminated.
02
Drugs
panitumumab
03
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT00667420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00667420.